Georgia's Online Cancer Information Center

Find A Clinical Trial

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Cancer Type
Multiple Myeloma
Plasma cell neoplasm
Trial Phase
Phase III
18 Years and older, Male and Female
Study Type
Protocol IDs
C1071007 (primary)
Study Sponsor
Pfizer Inc


The purpose of this study is to evaluate whether elranatamab monotherapy can provide
clinical benefit compared to lenalidomide monotherapy (control) in participants with
newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In
Part 1 and Part 2 of the study, participants in the study will either receive elranatamab
(arm A and C) as an injection under the skin at the study clinic or lenalidomide orally
once daily at home (arm B). Participation in the study will be approximately five years


Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells
and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.


  1. Diagnosis of MM as defined according to IMWG criteria (Rajkumar, 2014) with measurable disease at diagnosis
  2. Part 1 patients must be MRD positive, Part 2 patients can be MRD negative or MRD positive
  3. History of induction therapy for newly diagnosed MM, followed by high dose therapy and autologous stem cell transplant. Randomization must occur within 120 days from the stem cell transplant. For participants who receive consolidation therapy after ASCT, randomization must occur within 60 days of consolidation and within 7 months from ASCT.
  4. Partial Response or better according to IMWG criteria at the time of randomization
  5. Must have an archival bone marrow aspirate sample(s) to identify the dominant malignant (index) clone by central laboratory NGS test (ClonoSEQ assay) that is used to track MRD status. This sample should preferably be collected before induction treatment (eg, at diagnosis) or before transplant.
  6. ECOG performance status =1
  7. Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade = 1
  8. Not pregnant and willing to use contraception

Treatment Sites in Georgia

Winship Cancer Institute of Emory University

1365 Clifton Road NE
Building C
Atlanta, GA 30322

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.